AbbVie Inc (ABBV) Stock Analysis
Verdict: WATCH (do not buy)
Skyrizi and Rinvoq volume surging past Humira losses offsets near-term M&A dilution, but $70.8B debt and 74.5x GAAP P/E cap upside.
Investment score: 60/100
Analysis as of
Is AbbVie Inc stock worth reviewing? AI model thesis
The AI model considers AbbVie a HOLD at 264.34 USD. While operational momentum in next-generation immunology (Skyrizi, Rinvoq) and neuroscience (+26.0% Q1 2026 growth) effectively offsets Humira erosion, the current stock price sits near 52-week highs (269.39 USD) with an elevated TTM GAAP P/E of 74.49x and total debt of $70.82B.
7-factor investment score
- Valuation: 48/100 (weight 20%)
- Financial Health: 55/100 (weight 15%)
- Technical Momentum: 78/100 (weight 15%)
- Earnings Quality: 68/100 (weight 15%)
- Insider Sentiment: 35/100 (weight 10%)
- Analyst Consensus: 72/100 (weight 10%)
- Risk-Adjusted Return: 62/100 (weight 15%)
AbbVie Inc opportunities and risks
What speaks for ABBV
- Skyrizi and Rinvoq expansion replacing Humira volume
What speaks against ABBV
- Substantial leverage and negative stockholders' equity from M&A accounting
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| ABBV | 74.5x | 7.3x | 25.0x | 71.5% | 9.8% | 4.2% |
| AMGN | 25.6x | 5.9x | 16.2x | 72.7% | 22.9% | 4.5% |
| GILD | n/a | 6.1x | 330.5x | 79.6% | -10.6% | 7.1% |
| VRTX | 30.4x | 10.6x | 23.8x | 86.0% | 34.9% | 2.8% |
| Peer median | 25.6x | 6.1x | 23.8x | 79.6% | 22.9% | 4.5% |
Frequently asked questions about AbbVie Inc (ABBV)
Is ABBV stock a good investment?
The cached TradeMates AI model rates AbbVie Inc as WATCH (do not buy) with an investment score of 60/100. The AI model considers AbbVie a HOLD at 264.34 USD. While operational momentum in next-generation immunology (Skyrizi, Rinvoq) and neuroscience (+26.0% Q1 2026 growth) effectively offsets Humira erosion, the current stock price sits near 52-week highs (269.39 USD) with an elevated TTM GAAP P/E of 74.49x and total debt of $70.82B. This is algorithmic model output, not personal investment advice.
Is ABBV stock a buy?
The TradeMates model verdict for ABBV is WATCH (do not buy) with an investment score of 60/100. Treat this as a model signal to review, not a personal buy recommendation.